Jean Franchi Biography and Net Worth

CFO of Disc Medicine

Jean is an experienced CFO with over 30 years of finance leadership expertise at both public and private biotechnology companies of varying sizes across all stages of development. Most recently, she was the Chief Financial Officer of Replimune where she helped raise over $750 million across multiple financings and non-dilutive debt, supporting significant expansion while providing optionality in future capital formation for Replimune’s portfolio. Prior to Replimune, Jean served as Chief Financial Officer for Merrimack Pharmaceuticals, Dimension Therapeutics, which was acquired by Ultragenyx, and Good Start Genetics. Jean spent 16 years at Genzyme advancing within the organization during its most rapid phase of growth. She spent eight years at Genzyme as the Senior Vice President of Finance for all nine business units and then Senior Vice President of Corporate Finance working alongside the Chief Financial Officer and playing an important role in the approximately $20.1 billion sale to Sanofi. Jean holds a Bachelor’s in Business Administration from Hofstra University.

What is Jean M. Franchi's net worth?: The estimated net worth of Jean M. Franchi is at least $3.64 million as of February 18th, 2025. Franchi owns 69,530 shares of Disc Medicine stock worth more than $3,644,067 as of March 14th. This net worth evaluation does not reflect any other investments that Franchi may own. Learn More about Jean M. Franchi's net worth.
How old is Jean M. Franchi?: Franchi is currently 58 years old. There are 7 older executives and no younger executives at Disc Medicine. The oldest executive at Disc Medicine is Dr. Donald William Nicholson Ph.D., Executive Chairman, who is 66 years old. Learn More on Jean M. Franchi's age.
How do I contact Jean M. Franchi?: The corporate mailing address for Franchi and other Disc Medicine executives is 297 Boston Post Road #248, Wayland MA, 01778. Disc Medicine can also be reached via phone at 617-401-4400 and via email at ir@geminitherapeutics.com. Learn More on Jean M. Franchi's contact information.
Has Jean M. Franchi been buying or selling shares of Disc Medicine?: During the past quarter, Jean M. Franchi has sold $171,162.88 in Disc Medicine stock. Most recently, Jean M. Franchi sold 3,136 shares of the business's stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $54.58, for a transaction totalling $171,162.88. Following the completion of the sale, the chief financial officer now directly owns 69,530 shares of the company's stock, valued at $3,794,947.40. Learn More on Jean M. Franchi's trading history.
Who are Disc Medicine's active insiders?: Disc Medicine's insider roster includes Mona Ashiya (Director), Kevin Bitterman (Director), Joanne Bryce (CFO), Jean Franchi (CFO), Rahul Khara (Insider), Brian Macdonald (Insider), John Quisel (CEO), William Savage (Insider), Pamela Stephenson (Insider), William White (Director), and Jonathan Yu (COO). Learn More on Disc Medicine's active insiders.
Are insiders buying or selling shares of Disc Medicine?: During the last year, insiders at the sold shares 19 times. They sold a total of 395,005 shares worth more than $22,156,241.87. The most recent insider tranaction occured on March, 12th when Director Mona Ashiya sold 83,182 shares worth more than $4,529,259.90. Insiders at Disc Medicine own 4.2% of the company. Learn More about insider trades at Disc Medicine.
Information on this page was last updated on 3/12/2025.

Jean M. Franchi Insider Trading History at Disc Medicine

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
2/18/2025	Sell	3,136	$54.58	$171,162.88	69,530

Jean M. Franchi Buying and Selling Activity at Disc Medicine

Disc Medicine Company Overview

Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for the treatment of erythropoietic porphyrias, including erythropoietic protoporphyria, X-linked protoporphyria, and diamond-blackfan anemia; DISC-0974 for the treatment of anemia of myelofibrosis, and anemia of chronic kidney disease; and DISC-3405 for the treatment of polycythemia vera, and other hematologic disorders. The company's preclinical programs include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Disc Medicine, Inc. was founded in 2017 and is headquartered in Watertown, Massachusetts.

Today's Range

Now: $52.41

$52.36

$54.84

50 Day Range

MA: $56.62

$53.37

$63.82

2 Week Range

Now: $52.41

$25.60

$68.86

Volume

263,058 shs

Average Volume

359,832 shs

Market Capitalization

$1.81 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.73

Jean Franchi Biography and Net Worth

What is Jean M. Franchi's net worth?

How old is Jean M. Franchi?

How do I contact Jean M. Franchi?

Has Jean M. Franchi been buying or selling shares of Disc Medicine?

Who are Disc Medicine's active insiders?

Are insiders buying or selling shares of Disc Medicine?